Lisil-oxidasa (LOX) y proteinas tipo LOX: rol de amino-oxidasas, propiedades moleculares y cataliticas / Lysyl oxidase (LOX) and LOX-like proteins: role of amino-oxidases, molecular and catalytic properties / Lisil-oxidase (LOX) e proteinas tipo LOX: papel da amino-oxidases, propriedades moleculares e catalíticas

Las amino-oxidasas pertenecen a dos grupos de proteinas: flavoenzimas y quinoenzimas. La lisil-oxidasa (LOX) es una quinoenzima que contiene cobre y lisil-tirosil-quinona como cofactor. Los niveles de LOX aumentan en muchas enfermedades fibroticas y en algunos tumores promoviendo metastasis, mientras que la expresion de la enzima esta disminuida en enfermedades que involucran un deterioro en el metabolismo del cobre. Se discute el rol de LOX como amino-oxidasa en la catalisis de la desaminacion oxidativa de residuos de lisina en los precursores del colageno y de elastina, y la participacion de los restantes miembros de esta familia genica: LOXL1, LOXL2, LOXL3 y LOXL4, asi como sus propiedades moleculares. Se analizan su biosintesis, sus propiedades cataliticas y mecanismo de reaccion, cofactores e inhibidores y la expresion y respuesta a diversos efectores celulares.

Amino-oxidases belong to two groups of proteins: flavoenzymes and quinoenzymes. Lysyl oxidase (LOX) is a copper-containing quinoenzime, having lysyl-tyrosyl-quinone as cofactor. LOX levels are increased in many fibrotic diseases, and in some tumors promoting metastasis, while the enzyme expression is decreased in diseases that involve deterioration in copper metabolism. The role of LOX as amino oxidase in catalyzing the oxidative deamination of lysine residues in precursors of collagen and elastin is discussed, as well as the participation of other members of this gene family: LOXL1, LOXL2, LOXL3, and LOXL4, and their molecular properties. The biosynthesis, catalytic properties and reaction mechanism, cofactors and inhibitors, and the expression and response to various cellular effectors are analyzed.

As amina oxidases pertencem a dois grupos de proteínas: flavoenzimas e quinoenzimas. A lisil-oxidase (LOX) é uma quinoenzima contendo cobre e lisil-tirosil-quinona como cofator. Os níveis da enzima LOX aumentam em muitas doenças fibróticas e em alguns tumores promovendo metástase, enquanto que a expressão da enzima está reduzida em doenças que envolvem a deterioração no metabolismo do cobre. Discute-se o papel de LOX como amina oxidase na catálise a desaminação oxidativa de resíduos de lisina de precursores de colágeno e de elastina, e a participação dos outros membros desta família gênica: LOXL1, LOXL2, LOXL3 e LOXL4, bem como as suas propriedades moleculares. A sua biossíntese, as suas propriedades catalíticas e mecanismo de reação, cofatores e inibidores e a expressão e resposta a diversos efetores celulares são analisados.

Flavoproteínas que actúan como amino-oxidasas: Estructura, función e importancia clínica / Flavoproteins acting as amine oxidases: Structure, function and clinical significance / Flavoproteínas atuando como amina oxidases: Estrutura, função e significado clínico

Se destaca la actividad de las flavoenzimas como amino-oxidasas, que intervienen en el metabolismo de las aminas biogénicas como biorreguladores, especialmente en el crecimiento y la diferenciación celular. La clasificación de las amino-oxidasas incluye flavoenzimas y quinoenzimas. Se analizan las amino-oxidasas que son flavoproteínas, como las monoamino-oxidasas y las poliamino-oxidasas. Se discuten las isoformas, estructuras y función de ambas, sus sustratos e inhibidores, la expresión de MAO-A y MAO-B en tejidos humanos y sus implicancias clínicas. MAO plaquetaria es un biomarcador de desórdenes mentales y neurodegenerativos. Los inhibidores selectivos de MAO-A resultaron ser eficaces antidepresivos, mientras que algunos de MAO-B se utilizan en el tratamiento de enfermedades de Parkinson y de Alzheimer. La identificación de elevadas concentraciones de poliaminas en varias enfermedades, desde cáncer y psoriasis hasta infecciones parasitarias, hace que la manipulación de su metabolismo sea un blanco terapéutico o preventivo en ciertas enfermedades. Se discute además qué poliamino-oxidasas actúan en el metabolismo de las poliaminas en humanos, frente a las presentes en plantas, bacterias y protistas. Las poliaminas y las enzimas de su metabolismo desempeñan funciones relevantes en los procesos de envejecimiento y en algunas enfermedades, como cáncer, diabetes mellitus, accidentes cerebro-vasculares, insuficiencia renal y trastornos psiquiátricos.

The activity of flavoenzymes as amine oxidases involved in the metabolism of biogenic amines as bioregulators is highlighted, particularly for cell growth and differentiation. The classification of amine oxidases includes flavoenzymes and quinoenzymes. Amine oxidases that are flavoproteins, such as monoamine oxidases and polyamine oxidases, are analyzed herein. The isoforms, structures and functions of both enzyme families, their substrates and inhibitors, the expression of MAO-A and MAO-B in human tissues, and their clinical implications are discussed. Platelet MAO is a biomarker of mental and neurodegenerative disorders. Selective MAO-A inhibitors proved to be effective antidepressants, while some MAO-B inhibitors are used for treatment of Parkinson's and Alzheimer's diseases. The identification of high concentrations of polyamines in a variety of diseases, from psoriasis to cancer and parasitic infections, makes handling their metabolism a therapeutic or preventive target for the treatment of some diseases. Also polyamine oxidase activity on polyamine metabolism in humans, compared to those present in plants, bacteria and protists,is discussed. Polyamines and the enzymes involved in their metabolism play important roles in the aging processes, as well as in certain diseases such as cancer, diabetes mellitus, stroke, kidney failure, and defined psychiatric disorders.

Foi enfatizada a atividade de flavoenzimas como as amina oxidases envolvidas no metabolismo de aminas biogênicas como biorreguladores, especialmente no crescimento e diferenciação celular. A classificação das amina oxidases inclui flavoenzimas e quinoenzimas. Amina oxidases que são flavoproteínas, tais como monoamina oxidases e poliamina oxidases, são analisadas. Isoformas, estrutura e função das duas oxidases são discutidas, os seus substratos e inibidores, a expressão de MAO-A e MAO-B em tecidos humanos e suas implicações clínicas. MAO plaquetária é um biomarcador de desordens mentais e neurodegenerativas. Os inibidores selectivos da MAO-A resultaram ser eficazes antidepressivos, embora alguns dos MAO-B sejam utilizados no tratamento da doença de Parkinson e de Alzheimer. A identificação de elevadas concentrações de poliaminas em várias doenças, desde câncer e psoríase a infecções parasitárias, faz com que a manipulação do seu metabolismo seja um alvo terapêutico ou preventivo em certas doenças. Também se discute que a poliamina oxidase atua sobre o metabolismo das poliaminas no ser humano, em comparação com aquelas presentes em plantas, bactérias e protistas. As poliaminas e enzimas do seu metabolismo desempenham papéis relevantes nos processos de envelhecimento e em algumas doenças, tais como câncer, diabetes miellitus, acidente vascular cerebral, insuficiência renal e perturbações psiquiátricas.

Correlation between total nitrite/nitrate concentrations and monoamine oxidase (types A and B) and semicarbazide-sensitive amine oxidase enzymatic activities in human mesenteric arteries from non-diabetic and type 2 diabetic patients

The aim of this study was to determine the correlation between total nitrite/nitrate concentrations (NOx) and the kinetic parameters of monoamine oxidase enzymes (MAO-A and MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) in human mesenteric arteries. Arteries were from non-diabetic and type 2 diabetic patients with sigmoid or rectum carcinoma for whom surgery was the first option and who were not exposed to neo-adjuvant therapy. Segments of human inferior mesenteric arteries from non-diabetic (61.1 ± 8.9 years old, 7 males and 5 females, N = 12) and type 2 diabetic patients (65.8 ± 6.2 years old, 8 males and 4 females, N = 12) were used to determine NOx concentrations and the kinetic parameters of MAO-A, MAO-B and SSAO by the Griess reaction and by radiochemical assay, respectively. The NOx concentrations in arteries from diabetic patients did not differ significantly from those of the non-diabetic group (10.28 ± 4.61 vs 10.71 ± 4.32 nmol/mg protein, respectively). In the non-diabetic group, there was a positive correlation between NOx concentrations and MAO-B parameters: Km (r = 0.612, P = 0.034) and Vmax (r = 0.593, P = 0.042), and a negative correlation with the SSAO parameters: Km (r = -0.625, P = 0.029) and Vmax (r = -0.754, P = 0.005). However, in the diabetic group no correlation was found between NOx concentrations and the three kinetic parameters of the enzymes. These results suggest an important function of sympathetic nerves and vascular NOx concentrations in arteries of non-diabetic patients. Thus, these results confirm the importance of a balance between oxidants and antioxidants in the maintenance of vascular homeostasis to prevent oxidative stress.

Patterns of renal dopamine release to regulate diuresis and natriuresis during volume expansion: Role of renal monoamine-oxidase / Perfiles de secreción de dopamina renal en la expansión de volumen para regular diuresis y natriuresis: Rol de la monoaminoxidasa renal

Diuretic and natriuretic effects of renal dopamine (DA) are well established. However, in volume expansion the pattern of renal DA release into urine (U DA V) and the role of enzymes involved in DA synthesis/degradation have not yet been defined. The objective was to determine the pattern of U DA V during volume expansion and to characterize the involvement of monoamine-oxidase (MAO) and aromatic amino-acid decarboxylase (AADC) in this response. In this study male Wistar rats were expanded with NaCl 0.9% at a rate of 5% BWt per hour. At the beginning of expansion three groups received a single drug injection as follows: C (vehicle, Control), IMAO (MAO inhibitor Pargyline, 20 mg/kg BWt, i.v.) and BNZ (AADC inhibitor Benserazide, 25 mg/kg BWt, i.v.). Results revealed that in C rats U DA V (ng/30 min/100g BWt) increased in the first 30 min expansion from 11.5 ± 1.20 to 21.8 ± 3.10 (p < 0.05) and decreased thereafter. IMAO showed a similar pattern but significantly higher than C at 30 min expansion (32.5 ± 2.20, p < 0.05). IMAO greatly reduced MAO activity from 8.29 ± 0.35 to 1.1 ± 0.03 nmol/mg tissue/hour and significantly increased diuresis and natriuresis over controls. BNZ abolished the early U DA V peak to 3.2±0.72 (p < 0.01) and though, U DA V increased over C after 60 min expansion, natriuresis and diuresis were diminished by BNZ treatment. Results indicate that an increment in renal DA release into urine occurs early in expansion and in a peak-shaped way. In this response MAO plays a predominant role.

La dopamina (DA) intrarrenal ejerce efectos diuréticos y natriuréticos. Sin embargo, en los estado de expansión de volumen aún no está bien definido el patrón de liberación de dopamina renal hacia la orina y si cumplen un rol las enzimas involucradas en la síntesis o degradación de la amina. El objetivo del presente trabajo fue determinar el patrón de excreción urinaria de DA (U DA V) durante la expansión de volumen, caracterizando la participación de las enzimas monoaminooxidasa (MAO) y decarboxilasa de aminoácidos aromáticos (AADC) en esta respuesta. Para ello ratas Wistar macho fueron expandidas de volumen con NaCl 0.9% al 5% del peso corporal por hora durante dos horas y divididas en tres grupos, los que al comienzo de la expansión recibieron: C (vehículo, Control), IMAO (Pargilina, inhibidor de MAO, 20 mg/kg PC, i.v.) y BNZ (Benserazida, inhibidor de AADC, 25 mg/kg PC, i.v.). Se observó que en C la U DA V (ng/30min/100gPC) aumentó durante los primeros 30 minutos de expansión de 11.5 ± 1.20 a 21.8 ± 3.10 (p < 0.05), disminuyendo posteriormente. IMAO mostró un patrón de liberación similar pero significativamente mayor que C a los 30 min de expansión (32.5 ± 2.20, p < 0.05). En este grupo la actividad de MAO disminuyó de 8.29 ± 0.35 a 1.1 ± 0.03 nmol/mg tejido/hora y aumentaron la diuresis y natriuresis por sobre los controles. En BNZ, el pico de U DA V observado a los 30 min de la expansión disminuyó a 3.2 ± 0.72 (p < 0.01), aunque luego de 60 minutos fue mayor que en C. BNZ disminuyó tanto la diuresis como la natriuresis. Podemos concluir que al comienzo de la expansión de volumen se produce un pico de excreción de dopamina renal hacia la orina. La enzima MAO juega un rol fundamental en esta respuesta.

Effect of chlorpromazine, imipramine and lithium on MAO-A and MAO-B activity in rat brain mitochondria.

Drugs with efficacy in psychiatric disorders affect the function of central neurotransmitter amines, which are inactivated primarily by monoamine oxidase (MAO). Effect of these drugs on the two types of MAO (MAO-A and MAO-B) has been studied in rat brain. The result showed that chlorpromazine (CPZ) and imipramine (IMI) at concentrations of 1x10(-2), 5x10(-3) and 2.5x10(-3) M inhibited rat brain mitochondrial MAO-A activity in vitro by 82, 50, 39 and 86, 74, 38 %, respectively. CPZ at concentrations of 5x10(-3), 2.5x10(-3), 1x10(-3) M inhibited rat brain mitochondrial MAO-B activity in vitro by 83, 55, 39 %, respectively, while IMI at concentrations of 5x10(-4), 2.5x10(-4), 1x10(-4) M inhibited the in vitro enzyme activity by 43, 35, 21 %, respectively. Lithium at concentration of 5x10(-3) M could not either inhibit MAO-A or MAO-B in the mitochondrial fraction of rat brain.

Correlation of serotonin and monoamine oxidase levels with anxiety level in diarrhea-predominant irritable bowel syndrome.

BACKGROUND: Irritable bowel syndrome (IBS) is generally considered to have a psychogenic component in its physiopathology. AIM: To study the role of serotonin (5-hydroxytryptamine; 5-HT), monoamine oxidase (MAO) and anxiety, and to elucidate the relationship between these in patients with diarrhea-predominant IBS. METHODS: 5-HT and MAO activity and anxiety levels were studied in 20 healthy volunteers (aged 18-25 years; all men) and 57 patients with diarrhea-predominant IBS (30-60 years; all men). RESULTS: The concentrations of 5-HT (0.3 [0.04] microg/ mL) and MAO (15.5 [3.2] U/mL), and the anxiety level score (14.4 [2.9]) were significantly higher (p < 0.001) in patients than in healthy volunteers (0.1 [0.02], 6.4 [1.4] and 3.4 [1.2], respectively). These parameters correlated with each other in both patients and volunteers. CONCLUSIONS: Elevated 5-HT and MAO activity and anxiety may play a role in patients with diarrhea-predominant IBS.

Serotonin and benzylamine oxidation by type A and type B MAO of rat brain in presence of organophosphate pesticides.

Organophosphate (OP) pesticides, monocrotophos (MCP), dichlorvos (DDVP) and phosphamidon significantly inhibit both MAO-A and MAO-B activities in rat brain mitochondria. The inhibition of MAO-A by MCP is reversible whereas the inhibition by DDVP and phosphamidon is irreversible. MAO-B is inhibited irreversibly by all these organophosphates suggesting that the mechanism of action of OP pesticides is through phosphorylation of serine residue present in active centre of MAO.

Methyl parathion induced alterations in monoaminergic system of developing rat pups.

Methyl parathion induced alterations in the level of monoamines, viz. norepinephrine, dopamine and serotonin were studied in discrete regions of developing central nervous system of rat pups. A significant decrease in the level of monoamines noticed in methyl parathion toxicosis may be related to the altered neuronal activity and inefficiency, leading to depression and impairment in various behavioural activities. In contrast to AChE inhibition, monoamine oxidase (MAO) activity showed an increasing trend and it could cause deamination of catecholamines and accumulation of its metabolites. This suggests that an increased AChE inhibition may indirectly stimulate MAO activity in developing rat pups exposed to methyl parathion.

Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity.

Anxiogenic agents, yohimbine, pentylenetetrazole (PTZ), quinine, bufotenine, flumazenil and isatin were administered (ip) to rats at doses known to induce anxiety in this species. All the drugs exhibited anxiogenic response on the elevated plus-maze and induced a parallel increase in endogenous brain monoamine oxidase (MAO) inhibitory (tribulin) activity. The intensity of the drug-induced anxiety was fairly well correlated with the magnitude of increase in the MAO A inhibitory component of tribulin but not so with its MAO B inhibitory component. Thus, in the doses used, the degree of anxiogenic activity was PTZ > yohimbine > bufotenine > quinine > isatin > flumazenil, in terms of % entries on the open arms of the maze, whereas the magnitude of endogenous MAO A inhibition was PTZ > yohimbine > bufotenine > quinine > flumazenil > isatin. The results indicate that the MAO A inhibitory component of tribulin, rather than its MAO B inhibitory component, may be responsible for the postulated function of tribulin as an endogenous marker of anxiety.

Relationship between acetylcholinesterase and monoamine oxidase in brain regions of Oreochromis mossambicus exposed to phosalone.

The level of acetylcholinesterase (AChE) in brain regions of O. mossambicus at different intervals showed the extent of phosalone toxicity. Significant inhibition of AChE at the end of 96 hr in the brain regions was observed. In contrast to AChE inhibition, the monoamine oxidase (MAO) activity showed significant increase in the regions of cerebral hemispheres, dien/mesencephalon, cerebellum and medulla oblongata. The increase of MAO activity in the brain regions under phosalone toxicity is considered to be one of the mechanisms to maintain the amines level in O. mossambicus.

Regional alterations in the monoamine levels, monoamine oxidase activity & neurobehavioural effects in rats treated with Dimecron (phosphamidon).

Monoamine levels, MAO activity and neurobehavioral perturbations were studied in albino rats intoxicated with Dimecron i.e., phosphamidon (2.0 mg/kg b wt, ip x 7 days). Open field behaviour (OFB) of the rats was examined thrice a day for seven days. Significant depletion in DA, NE and 5-HT, and enhancement of MAO were found in various regions of the central nervous system (CNS) on the 7th day. Daily decrease was observed in ambulation, rearing and preening responses, with maximum decrement on the seventh day of Dimecron intoxication.

Iron deficiency anemia and catecholamine metabolism.

To assess the effects of iron therapy on platelet monoamine oxidase (MAO) activity and urinary excretion of total metanephrines (MN) in infants and young children with iron deficiency anemia, 24 subjects were tested before and after one month of oral iron treatment. Thirteen healthy children comprised the control group. In the control group, platelet MAO level was 0.21 +/- 0.02 U/mg protein (mean +/- SE), urinary total metanephrine was 2.51 +/- 0.47 micrograms/mg creatinine. In cases with iron deficiency, mean platelet MAO level was 47.6% lower (p less than 0.005) whereas mean urinary metanephrine plus normetanephrine (MN-NMN) was only 20.7% lower (p greater than 0.05) than the control values. After one month, the anemic patients receiving oral iron therapy showed a significant increase in hemoglobin concentration, per cent transferrin saturation and platelet MAO activity (p less than 0.05). However, urinary metanephrine excretion was found to be lower in this group when compared to the metanephrine levels in iron deficiency before the medication (p less than 0.05). Although hemoglobin and transferrin saturation did not return to normal levels, these findings suggested that platelet MAO activity increased and urinary excretion of metanephrines decreased after iron medication.

Monoamineoxidase activity in certain brain regions associated with xanthurenic acid excretion in rats on oral contraceptive steroids.

Monoamineoxidase (MAO) activity in some regions of brain and urinary xanthurenic acid were investigated in female rats administered with oral contraceptive (OC) steroids-ethynyl estradiol (Ees), lynestrenol (Ly) and both in combination (Cm) for 75 days. The MAO activity was reduced significantly in most regions specially in cortex-the extent of reduction being 65 per cent with Ees, 51 per cent with Ly and 69 per cent with Cm treatments. In the hypothalamus, the activity was decreased by 50 per cent with Ees, 38 per cent with Ly and by 40 per cent with Cm treatments. In the corpus striatum the activity was reduced by 14 per cent with Ly treatment, 25 per cent with Cm treatment and in the midbrain by 59 per cent with Ees treatment only. The concentration of xanthurenic acid in urine was higher by 55 per cent with Ees, 109 per cent with Ly and by 120 per cent with Cm treatments. These changes in MAO activity and level of xanthurenic acid excretion indicate the possible alteration in the metabolism of neurotransmitter, associated with prolonged use of OC.

A colorimetric method for assay of serotonin deamination by monoamine oxidase.

The present method involves conversion of the aldehyde produced, as a result of serotonin deamination by monoamine oxidase, to its 2:4 dinitrophenyl hydrazone derivative which gives a stable, bright yellow colour in alkaline solution and can be measured colorimetrically. The derivative is however unstable in the acidic medium and has to be extracted into an organic solvent immediately. The details of the method and its standardization are discussed.

Abnormal catecholamine metabolism in pheochromocytoma

En este trabajo se analizan los niveles y características de las enzimas involucradas en la biosíntesis y degradación de las catecolaminas (CA) en el feocromocitoma y la correlación existente con la secreción de las mismas con el propósito de evaluar las alteraciones que podrían existir y explicar así la mayor liberación de CA por el tejido tumoral. Se estudiaron 10 feocromocitomas y 5 adrenales controles en los que se evaluó la actividad de las enzimas de síntesis: tirosina hidroxilasa (TH), aminoácido descarboxilasa (DC), dopamina ß hidroxilasa (DBH), feniletanolamina-N-metil transferasa (PNMT) y de degradación: catecol-0-metil transferasa (COMT) y monoaminooxidasa (MAO). Con respecto a TH se estudiaron además sus propiedades cinéticas así como su activación por AMP. Los resultados de actividad enzimática fueron comparadas con los valores de excreción urinaria de catecolaminas. Se encontró una mayor actividad de TH (p<0,001). DC(p<0,001) y de DBH(p<0,01) en el feocromocitoma en comparación con la médula adrenal humana normal y, en cambio, las actividades de las enzimas de degradación, MAO y COMT estaban muy disminuidas (p <0,001 y 0,01, respectivamente). Los estudios cinéticos demostraron que la TH de feocromocitoma tenía una mayor afinidad por su cofactor pteridínico reducido (20%) y una menor sensibilidad a la inhibición por producto ya que la IC de NA fue 3 veces mayor que en la adrenal control. La proporción de TH encontrada bajo la forma soluble o particulada fue similar en el tejido tumoral o en la médula adrenal, siendo también similares los niveles tisulares de sustrato tirosina (controles 21,2 + ou - 2,1microng/g; tumor 23,2 + ou - 3,4microng/g). La activación de esta enzima por dibutiril AMP cíclico tampoco se observó modificada en el tumor. Existe una estrecha correlación entre la CA secretada y la presencia de la enzima PNMT en el tumor, siendo los niveles de esta enzima en los tumores secretores de adrenalina similares a los de médula adrenal y muy bajos o indetectables en los tumores secretores de NA. Consideramos entonces que en el feocromocitoma estas alteraciones metabólicas conducirían a un nivel endógeno de CA elevado que podría liberarse sin catabolizarse por mecanismos aún no dilucidados